奥利司他在2型糖尿病中的体重管理:电子健康记录研究
基于英国CPRD Aurum全科医疗数据库的队列研究,纳入2016-2017年新诊断2型糖尿病或糖尿病前期的成人患者,分析奥利司他处方与患者特征的关系及与体重下降的关联。结果显示奥利司他处方率低(2型糖尿病0.8%,糖尿病前期0.7%),持续使用≥12周者达到≥5%体重下降的可能性更高(AOR 1.69,95%CI 1.07-2.67),但早期停药常见。
要点
- 奥利司他在新诊断2型糖尿病或糖尿病前期患者中处方率很低(约0.7%-0.8%)。
- 持续使用奥利司他≥12周与≥5%体重下降显著相关(AOR 1.69,95%CI 1.07-2.67)。
- 年轻、女性、贫困地区、当前吸烟、合用二甲双胍及高血压者更可能被处方奥利司他。
核心结论
- 奥利司他在2型糖尿病和糖尿病前期患者中与体重下降显著相关,但处方不频繁且常被早期停用。
主要发现
- 与未使用奥利司他者相比,持续使用≥12周者达到≥5%体重下降的调整比值比(AOR)为1.69(95%CI 1.07-2.67)。
- 早期停用奥利司他者达到≥5%体重下降的AOR为0.56(95%CI 0.29-1.09)。
- 年轻、女性、贫困地区、当前吸烟、合用二甲双胍及记录有高血压者被处方奥利司他的可能性显著更高;基线糖化血红蛋白较高与早期停药相关。
临床怎么用
- 对于2型糖尿病或糖尿病前期患者,可考虑将奥利司他作为生活方式干预的辅助体重管理选项。
- 应关注持续用药≥12周对体重下降的重要性,并识别早期停药的风险因素。
局限性
- 奥利司他处方率低且早期停药常见,可能影响结果的普适性;研究为观察性设计,无法完全排除混杂。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Orlistat is recommended as an adjunct to diet and exercise for weight loss in the treatment of type 2 diabetes mellitus (T2DM). AIM: To explore associations between patient characteristics and orlistat prescribing, and to determine associations of orlistat with weight loss in T2DM and prediabetes. DESIGN AND SETTING: Cohort study using anonymised health records from a UK database of general practice. METHOD: The UK Clinical Practice Research Datalink (CPRD) Aurum database was searched to compile a cohort of patients aged ≥18 years, first diagnosed with T2DM or prediabetes in 2016 or 2017. Once the data had been collated, multivariable logistic regression models were used to determine associations with starting orlistat and stopping it early (<12 weeks of prescriptions) and orlistat's associations with weight loss in those who had not been prescribed second-line antidiabetic medications. RESULTS: Out of 100 552 patients with incident T2DM or prediabetes, 655 (0.8%) patients with T2DM and 128 (0.7%) patients with prediabetes were prescribed orlistat. Younger people, females, those in areas of deprivation, current smokers, those coprescribed metformin, and those recorded as having hypertension were statistically significantly more likely to be prescribed orlistat; higher baseline glycated haemoglobin levels were associated with early stopping. In comparison with patients not on orlistat, those who continued using it for ≥12 weeks were more likely to lose ≥5% weight (adjusted odds ratio [AOR] 1.69, 95% confidence interval [CI] = 1.07 to 2.67) but those who stopped orlistat early were less likely to lose ≥5% weight (AOR 0.56, 95% CI = 0.29 to 1.09). CONCLUSION: Orlistat was significantly associated with weight loss in patients with T2DM and prediabetes when taken for at least 12 weeks; however, it was infrequently prescribed and often taken for <12 weeks. Orlistat may be a useful adjunct to lifestyle modifications for patients with T2DM and prediabetes, but barriers to continued use means it may not be effective for everyone in managing weight loss.
引用
- Ghosal S, Heron N, Mason KJ, et al. Weight management with orlistat in type 2 diabetes: an electronic health records study. Br J Gen Pract. 2024. PMID: 38621802. doi:10.3399/BJGP.2023.0684
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。